Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (9955)	10/22/1997 2:35:00 AM
From: Andrew H	Read Replies (1) \| Respond to of 32384

Hey V1 thanks for the Acrobat info. With regard to the mystery drug, I had the impression from Henry that LGND may well have the drug selected (this drug is apparently in P3 trials, already). However, if they have it picked out, as you say, why not just make it part of the deal. I think at this point LGND would prefer a drug that would make them profitable in 99, rather than an extra possible 1.5% of Targretin royalties 4 or 5 years down the road. Of course if they don't select the LLY drug, they get an additional equity investment of 20M at 20% above the market price. We should know fairly soon since they only have 90 days after Nov. 3 to decide. Both LGND and the deal are looking better and better. As for enjoying the ride, I will like it a lot more if it proceeds primarily in a forward direction. (:>)